Nexigen GmbH

Nexigen GmbH develops innovative drugs with novel mode of action for indications with unmet medical need. Its proprietary drugs target disease mechanisms, which common technology is unable to address. Nexigen’s technology is able to aim at those disease relevant proteins which are not accessible by small molecule and antibody therapeutics. Therefore Nexigen’s drug development closes the significant gap between small molecule drugs and therapeutic antibodies.

The company currently focuses on drug discovery in anti-viral and cancer indications. Its technology platform is however broadly applicable to various indications. Nexigen is building its drug development business on selective partnerships in life science industry.